Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Basis of preparation (Tables)

Basis of preparation (Tables)
12 Months Ended
Dec. 31, 2021
The Company’s subsidiary is the following:

These consolidated financial statements incorporate the financial statements of the Company and its 100% owned subsidiary. The accounts of the Company’s subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated. The Company’s subsidiary is the following:


Name Place of Incorporation Ownership Percentage
XORTX Pharma Corp.